Suggested remit: To appraise the clinical and cost effectiveness of setmelanotide within its marketing authorisation for treating acquired hypothalamic obesity in people 4 years and over.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6542
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6542:
- 11 December 2025 - 16 January 2026
- Expected publication:
- 10 February 2027
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 December 2025 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 21 March 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual